ArticleNanomaterials (Basel, Switzerland)2018
Drug Delivery System for Emodin Based on Mesoporous Silica SBA-15.
Article in Nanomaterials (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Natural products as therapeutic interventions for inflammation-mediated cancer.Discover oncology · 2025Review
- Advanced Nanomaterials Functionalized with Metal Complexes for Cancer Therapy: From Drug Loading to Targeted Cellular Response.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Advances in nano drug delivery systems for enhanced efficacy of emodin in cancer therapy.International journal of pharmaceutics: X · 2025Review
- Triphenyltin(IV) Carboxylates with Exceptionally High Cytotoxicity against Different Breast Cancer Cell Lines.Biomolecules · 2023Article
- Anticancer Potential of Xanthohumol and Isoxanthohumol Loaded into SBA-15 Mesoporous Silica Particles against B16F10 Melanoma Cells.Materials (Basel, Switzerland) · 2022Article
- APTES-Modified SBA-15 as a Non-Toxic Carrier for Phenylbutazone.Materials (Basel, Switzerland) · 2022Article
- The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers.International journal of biological sciences · 2022Review
- Review
- Fighting viruses with materials science: Prospects for antivirus surfaces, drug delivery systems and artificial intelligence.Dental materials : official publication of the Academy of Dental Materials · 2021Review
- Plant-Derived Natural Products in Cancer Research: Extraction, Mechanism of Action, and Drug Formulation.Molecules (Basel, Switzerland) · 2020Review
- Effects of 8-hydroxyquinoline-coated graphene oxide on cell death and apoptosis in MCF-7 and MCF-10 breast cell lines.Iranian journal of basic medical sciences · 2020Article
- The Crotoxin:SBA-15 Complex Down-Regulates the Incidence and Intensity of Experimental Autoimmune Encephalomyelitis Through Peripheral and Central Actions.Frontiers in immunology · 2020Article
- Hydrogenation of alkyl-anthraquinone over hydrophobically functionalized Pd/SBA-15 catalysts.RSC advances · 2019Article
- The interaction between SBA-15 derivative loaded with PhJournal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2019Article
- Chlorambucil Conjugated Ugi Dendrimers with PAMAM-NH₂ Core and Evaluation of Their Anticancer Activity.Pharmaceutics · 2019Article
- Emodin inhibits colon cancer by altering BCL-2 family proteins and cell survival pathways.Cancer cell international · 2019Article
- Mesoporous silica nanoparticles SBA-15 loaded with emodin upregulate the antioxidative defense of Euproctis chrysorrhoea (L.) larvae.Turkish journal of biology = Turk biyoloji dergisi · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study mesoporous silica SBA-15 was evaluated as a vehicle for the transport of cytotoxic natural product emodin (EO). SBA-15 was loaded with different quantities of EO (SBA-15|EO1⁻SBA-15|EO5: 8⁻36%) and characterized by traditional methods. Several parameters (stabilities) and the in vitro behavior on tumor cell lines (melanoma A375, B16 and B16F10) were investigated. SBA-15 suppresses EO release in extremely acidic milieu, pointing out that EO will not be discharged in the stomach. Furthermore, SBA-15 protects EO from photodecomposition. In vitro studies showed a dose dependent decrease of cellular viability which is directly correlated with an increasing amount of EO in SBA-15 for up to 27% of EO, while a constant activity for 32% and 36% of EO in SBA-15 was observed. Additionally, SBA-15 loaded with EO (SBA-15|EO3) does not disturb viability of peritoneal macrophages. SBA-15|EO3 causes inhibition of tumor cell proliferation and triggers apoptosis, connected with caspase activation, upregulation of Bax, as well as Bcl-2 and Bim downregulation along with amplification of poly-(ADP-ribose)-polymerase (PARP) cleavage fragment. Thus, the mesoporous SBA-15 is a promising carrier of the water-insoluble drug emodin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.